8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk of anaphylaxis after vaccination in children and adults

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Anaphylaxis is a potentially life-threatening allergic reaction. The risk of anaphylaxis after vaccination has not been well described in adults or with newer vaccines in children.

          Objective

          We sought to estimate the incidence of anaphylaxis after vaccines and describe the demographic and clinical characteristics of confirmed cases of anaphylaxis.

          Methods

          Using health care data from the Vaccine Safety Datalink, we determined rates of anaphylaxis after vaccination in children and adults. We first identified all patients with a vaccination record from January 2009 through December 2011 and used diagnostic and procedure codes to identify potential anaphylaxis cases. Medical records of potential cases were reviewed. Confirmed cases met the Brighton Collaboration definition for anaphylaxis and had to be determined to be vaccine triggered. We calculated the incidence of anaphylaxis after all vaccines combined and for selected individual vaccines.

          Results

          We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95% CI, 0.90-1.84) per million vaccine doses. The incidence did not vary significantly by age, and there was a nonsignificant female predominance. Vaccine-specific rates included 1.35 (95% CI, 0.65-2.47) per million doses for inactivated trivalent influenza vaccine (10 cases, 7,434,628 doses given alone) and 1.83 (95% CI, 0.22-6.63) per million doses for inactivated monovalent influenza vaccine (2 cases, 1,090,279 doses given alone). The onset of symptoms among cases was within 30 minutes (8 cases), 30 to less than 120 minutes (8 cases), 2 to less than 4 hours (10 cases), 4 to 8 hours (2 cases), the next day (1 case), and not documented (4 cases).

          Conclusion

          Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat.

          Related collections

          Author and article information

          Journal
          1275002
          4431
          J Allergy Clin Immunol
          J. Allergy Clin. Immunol.
          The Journal of allergy and clinical immunology
          0091-6749
          1097-6825
          23 October 2015
          06 October 2015
          March 2016
          01 March 2017
          : 137
          : 3
          : 868-878
          Affiliations
          [a ]The Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta
          [b ]Southern California Kaiser Permanente, Pasadena
          [c ]Kaiser Permanente Vaccine Study Center, Oakland
          [d ]the Institute for Health Research, Kaiser Permanente, Denver
          [e ]the Department of Population Medicine, Harvard Medical School and the Harvard Pilgrim Health Care Institute, Boston
          [f ]Group Health Research Institute, Seattle
          [g ]The Center for Health Research, Kaiser Permanente Northwest, Portland
          [h ]The Marshfield Clinic Research Foundation, Marshfield
          [i ]The HealthPartners Institute for Education and Research, Minneapolis
          [j ]Kaiser Permanente Center for Health Research, and the Rollins School of Public Health, Emory University, Atlanta
          Author notes
          Corresponding author: Michael M. McNeil, MD, MPH, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS D-26, Atlanta, GA 30333. mmm2@ 123456cdc.gov .
          Article
          PMC4783279 PMC4783279 4783279 nihpa732076
          10.1016/j.jaci.2015.07.048
          4783279
          26452420
          7b4f4966-4eca-4a29-92f2-376a01493c81
          History
          Categories
          Article

          Anaphylaxis,vaccine safety,immunization
          Anaphylaxis, vaccine safety, immunization

          Comments

          Comment on this article